Meet the MedCity Media Team

And take 2 minutes to help us make MedCityNews.com better for you.

Every year, we ask you to tell us a little about yourself (anonymously) to help us create better, more relevant content and features for you. We consider every response and very much appreciate you taking the time to assist us.

Please click the button above to open a simple, multiple choice survey that should only take 2 minutes to complete.

Thank you,

The MedCity Media Team

Abbott, Boston Scientific claim 64 percent of U.S. drug-eluting stent market

4:30 pm by | 0 Comments

Abbott Laboratories (NYSE:ABT) and Boston Scientific Corp. (NYSE:BSX) came out as the big players in the U.S. drug-eluting stent market, together staking claim to more than half of all DES revenues.

In 2010, Boston Scientific reported $1.5 billion in DES sales and held a 33 percent market share in the U.S., led by its Taxus and Promus stents.

The Taxus stent competes with Medtronic Inc.’s (NYSE:MDT)┬áResolute DES, and Medtronic recently announced data touting Resolute as the better option for avoiding in-stent late lumen loss.

BSX could gain even more market share if predictions pan out. Analysts in June foresaw much of the stent business left behind by Johnson & Johnson (NYSE:JNJ) subsidiary Cordis Corp. moving over to Boston Scientific.

Advertisement

Abbott came in at $1.4 billion in sales, with a 31 percent corner on the market driven by its Xience DES, according to market research firm CompaniesandMarkets.com’s report.

The global market for drug-eluting stents was valued at $1.7 billion in 2003 and saw 15 percent annual growth, coming to $4.6 billion in 2010. The market is expected to idle in the near future as average selling prices decrease, but volume of sales is expected to grow with increasing adoption.

The U.S. market remains the largest in the world, according to the report, rounding out at about $2 billion in 2010, having doubled since 2003 when the number of implanted drug-eluting stents was estimated at 440,000. The number of DES implanted in 2010 came to 1.2 million.

Abbott Labs was ranked 1st in the the MassDevice Big 100 list of the world’s largest medical device companies. Boston Scientific ranked 10th.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

MassDevice Staff

By MassDevice Staff

The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
Visit website | More posts by Author

0 comments